Treating menopause — MHT and beyond

[1]  C. Lohse,et al.  Association of Premenopausal Bilateral Oophorectomy With Cognitive Performance and Risk of Mild Cognitive Impairment , 2021, JAMA network open.

[2]  Navneet Matharu,et al.  Oestrogen engages brain MC4R signalling to drive physical activity in female mice , 2021, Nature.

[3]  J. Abbott,et al.  Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial. , 2021, JAMA.

[4]  James H. Liu.  The Role of Progestogens in Menopausal Hormone Therapy. , 2021, Clinical obstetrics and gynecology.

[5]  C. Castelo-Branco,et al.  Vaginal laser therapy for genitourinary syndrome of menopause - systematic review. , 2021, Maturitas.

[6]  G. Emons,et al.  Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review , 2021, Journal of Cancer Research and Clinical Oncology.

[7]  A. Abu-Zaid,et al.  The effect of tibolone treatment on lipid profile in women: a systematic review and dose-response meta-analysis of randomized controlled trials. , 2021, Pharmacological research.

[8]  L. Rubin,et al.  Cognitive profiles in perimenopause: hormonal and menopausal symptom correlates , 2021, Climacteric : the journal of the International Menopause Society.

[9]  J. Foidart,et al.  Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function. , 2021, Contraception.

[10]  R. Brinton,et al.  Precision hormone therapy: identification of positive responders , 2021, Climacteric : the journal of the International Menopause Society.

[11]  L. Cardozo.  Faculty Opinions recommendation of The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[12]  I. Lambrinoudaki,et al.  Premature ovarian insufficiency: a toolkit for the primary care physician , 2021, Climacteric : the journal of the International Menopause Society.

[13]  S. Fleming,et al.  A review of the pathophysiology of functional hypothalamic amenorrhoea in women subject to psychological stress, disordered eating, excessive exercise or a combination of these factors , 2020, Clinical endocrinology.

[14]  Marcus Schmidt,et al.  Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer , 2020, Journal of Cancer Research and Clinical Oncology.

[15]  J. Hippisley-Cox,et al.  Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases , 2020, BMJ.

[16]  N. Panay,et al.  Vaginal lubricants and moisturizers: a review into use, efficacy, and safety , 2020, Climacteric : the journal of the International Menopause Society.

[17]  C. Tempfer,et al.  Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review , 2020, Cancers.

[18]  E. Lundström,et al.  Progestogen addition with low-dose levonorgestrel intrauterine system in menopausal hormone treatment gives less normal breast tissue proliferation than oral norethisterone acetate or medroxyprogesterone acetate , 2020, Hormone molecular biology and clinical investigation.

[19]  J. Manson,et al.  Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. , 2020, JAMA.

[20]  J. Coles,et al.  Australian women’s understanding of menopause and its consequences: a qualitative study , 2020, Climacteric : the journal of the International Menopause Society.

[21]  M. Hickey,et al.  Managing vasomotor symptoms effectively without hormones , 2020, Climacteric : the journal of the International Menopause Society.

[22]  E. Colli,et al.  Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime , 2020, BMC Women's Health.

[23]  J. Foidart,et al.  A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety , 2020, Menopause.

[24]  D. Apter,et al.  Oestrogen-free oral contraception with a 4 mg drospirenone-only pill: new data and a review of the literature , 2020, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[25]  N. Santoro,et al.  A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause , 2020, Menopause.

[26]  M. Kerr,et al.  Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial , 2020, Menopause.

[27]  Jing Zhang,et al.  Efficacy and Safety of Gabapentin and Pregabalin in Patients with Vasomotor Symptoms: a Systematic Review and Meta-Analysis. , 2019, American journal of obstetrics and gynecology.

[28]  V. Beral,et al.  Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence , 2019, The Lancet.

[29]  R. Eastell,et al.  Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. , 2019, The Journal of clinical endocrinology and metabolism.

[30]  J. Manson,et al.  The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? , 2019, Menopause.

[31]  F. Ramezani Tehrani,et al.  The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis , 2019, Climacteric : the journal of the International Menopause Society.

[32]  E. Kontopantelis,et al.  Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part II: Evaluation of tolerability and safety. , 2019, Maturitas.

[33]  J. Hippisley-Cox,et al.  Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases , 2019, British Medical Journal.

[34]  I. Lambrinoudaki,et al.  Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. , 2019, European journal of endocrinology.

[35]  C. Stuenkel.  The 2017 hormone therapy position statement of The North American Menopause Society , 2018, Menopause.

[36]  W. Bobo,et al.  Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. , 2018, Menopause.

[37]  S. Davis,et al.  Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors , 2018, The Journal of clinical endocrinology and metabolism.

[38]  Ji-ping Wang,et al.  Effect of a tissue selective estrogen complex on breast cancer: Role of unique properties of conjugated equine estrogen , 2018, International journal of cancer.

[39]  J. Pickar,et al.  Tissue selective estrogen complex (TSEC): a review , 2018, Menopause.

[40]  F. Urano,et al.  Estrogens Promote Misfolded Proinsulin Degradation to Protect Insulin Production and Delay Diabetes. , 2018, Cell reports.

[41]  I. Goldstein,et al.  The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review , 2018, Menopause.

[42]  A. Hevener,et al.  The impact of ERα action on muscle metabolism and insulin sensitivity – Strong enough for a man, made for a woman , 2018, Molecular metabolism.

[43]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[44]  M. Nyberg,et al.  Effects of menopause and high-intensity training on insulin sensitivity and muscle metabolism , 2017, Menopause.

[45]  J. Manson,et al.  Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study , 2017, Menopause.

[46]  S. Khosla,et al.  Regulation of Bone Metabolism by Sex Steroids. , 2018, Cold Spring Harbor perspectives in medicine.

[47]  C. Loprinzi,et al.  Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance) , 2018, Supportive Care in Cancer.

[48]  R. Santen,et al.  Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors , 2017, The Journal of clinical endocrinology and metabolism.

[49]  J. Foidart,et al.  Estetrol, a Fetal Selective Estrogen Receptor Modulator, Acts on the Vagina of Mice through Nuclear Estrogen Receptor α Activation. , 2017, The American journal of pathology.

[50]  A. Seftel.  Re: Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review. , 2017, The Journal of urology.

[51]  Daniel Henrion,et al.  Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications. , 2017, Physiological reviews.

[52]  S. Davis,et al.  Moderate-Severe Vasomotor Symptoms Are Associated with Moderate-Severe Depressive Symptoms. , 2017, Journal of women's health.

[53]  J. Foidart,et al.  Pharmacodynamic effects of the fetal estrogen estetrol in postmenopausal women: results from a multiple-rising-dose study , 2017, Menopause.

[54]  L. Huson,et al.  Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial , 2017, The Lancet.

[55]  P. Tobler,et al.  Ovarian hormones and obesity. , 2017, Human reproduction update.

[56]  S. Mirkin,et al.  The Women's EMPOWER Survey: Identifying Women's Perceptions on Vulvar and Vaginal Atrophy and Its Treatment. , 2017, The journal of sexual medicine.

[57]  L. Esserman,et al.  Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial , 2017, JAMA oncology.

[58]  S. Davis,et al.  Clinical audit of estradiol implant therapy: Long duration of action and implications in non-hysterectomised women. , 2016, Maturitas.

[59]  J. Simon,et al.  Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial , 2016, Menopause.

[60]  N. Magrini,et al.  Short-term and long-term effects of tibolone in postmenopausal women. , 2016, The Cochrane database of systematic reviews.

[61]  O. Franco,et al.  Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis. , 2016, JAMA cardiology.

[62]  A. Lethaby,et al.  Local oestrogen for vaginal atrophy in postmenopausal women. , 2016, The Cochrane database of systematic reviews.

[63]  V. Henderson,et al.  Cognitive effects of estradiol after menopause , 2016, Neurology.

[64]  S. Davis,et al.  Menopausal vasomotor symptoms are associated with poor self-assessed work ability. , 2016, Maturitas.

[65]  Wendy J Mack,et al.  Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. , 2016, The New England journal of medicine.

[66]  N. Panay,et al.  2016 IMS Recommendations on women’s midlife health and menopause hormone therapy , 2016, Climacteric : the journal of the International Menopause Society.

[67]  S. Davis,et al.  Low use of effective and safe therapies for moderate to severe menopausal symptoms: a cross-sectional community study of Australian women , 2016, Menopause.

[68]  Xinyan Jiang,et al.  Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials , 2015, Menopause.

[69]  M. Murad,et al.  Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. , 2015, The Journal of clinical endocrinology and metabolism.

[70]  R. V. Van Pelt,et al.  Timing of Estradiol Treatment After Menopause May Determine Benefit or Harm to Insulin Action. , 2015, The Journal of clinical endocrinology and metabolism.

[71]  M. Gissler,et al.  Increased Cardiovascular Mortality Risk in Women Discontinuing Postmenopausal Hormone Therapy. , 2015, The Journal of clinical endocrinology and metabolism.

[72]  S. Davis,et al.  Moderate-severely bothersome vasomotor symptoms are associated with lowered psychological general wellbeing in women at midlife. , 2015, Maturitas.

[73]  T. Simoncini,et al.  Estetrol Modulates Endothelial Nitric Oxide Synthesis in Human Endothelial Cells , 2015, Front. Endocrinol..

[74]  K. Schenck-Gustafsson,et al.  EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms. , 2015, Maturitas.

[75]  S. Davis,et al.  Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years , 2015, Menopause.

[76]  Frederick Naftolin,et al.  Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study , 2015, PLoS medicine.

[77]  S. Crawford,et al.  Duration of menopausal vasomotor symptoms over the menopause transition. , 2015, JAMA internal medicine.

[78]  M. Fukuda,et al.  Estrogens prevent metabolic dysfunctions induced by circadian disruptions in female mice. , 2015, Endocrinology.

[79]  Anne Eisinga,et al.  Hormone therapy for preventing cardiovascular disease in post-menopausal women. , 2015, The Cochrane database of systematic reviews.

[80]  S. Davis,et al.  Prevalence of menopausal symptoms in Asian midlife women: a systematic review , 2015, Climacteric : the journal of the International Menopause Society.

[81]  R. Santen.  Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels , 2015, Climacteric : the journal of the International Menopause Society.

[82]  C. Labrie,et al.  Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy , 2015, Climacteric : the journal of the International Menopause Society.

[83]  S. Bloom,et al.  Neurokinin B Administration Induces Hot Flushes in Women , 2015, Scientific Reports.

[84]  H. Depypere,et al.  The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review , 2015, Climacteric : the journal of the International Menopause Society.

[85]  A. N. McLendon,et al.  Ospemifene for the Treatment of Vulvovaginal Atrophy and Dyspareunia in Postmenopausal Women , 2014, Pharmacotherapy.

[86]  S. Davis,et al.  A Practitioner's Toolkit for Managing the Menopause , 2014, Climacteric : the journal of the International Menopause Society.

[87]  M. Mcdermott,et al.  Cognition and mood in perimenopause: A systematic review and meta-analysis , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[88]  A. Pinto-Neto,et al.  Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial. , 2014, The journal of sexual medicine.

[89]  J. George,et al.  The kisspeptin-GnRH pathway in human reproductive health and disease , 2014, Human reproduction update.

[90]  J. Simon,et al.  Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. , 2014, Maturitas.

[91]  D. Travers-Gustafson,et al.  Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: A Pilot Study of the Effects of Vaginal Testosterone Therapy , 2014, Sexual medicine.

[92]  G. Bachmann,et al.  Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy , 2013, Climacteric : the journal of the International Menopause Society.

[93]  J. Cappelleri,et al.  Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials. , 2014, Journal of women's health.

[94]  L. Kangas,et al.  Tissue selectivity of ospemifene: Pharmacologic profile and clinical implications , 2013, Steroids.

[95]  B. Komm,et al.  Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model , 2013, Climacteric : the journal of the International Menopause Society.

[96]  Jennifer G. Robinson,et al.  Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. , 2013, JAMA internal medicine.

[97]  A. A. Romanovsky,et al.  Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: A novel hypothesis on the mechanism of hot flushes , 2013, Frontiers in Neuroendocrinology.

[98]  P. Hannaford,et al.  Factors associated with resilience or vulnerability to hot flushes and night sweats during the menopausal transition , 2012, Menopause.

[99]  Hsin-Chieh Yeh,et al.  Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.

[100]  A. Perrone,et al.  Androgen receptor expression in the human vagina under different physiological and treatment conditions , 2013, International Journal of Impotence Research.

[101]  P. Chedraui,et al.  Understanding weight gain at menopause , 2012, Climacteric : the journal of the International Menopause Society.

[102]  M. Mapstone,et al.  Reconciling subjective memory complaints with objective memory performance in the menopausal transition , 2012, Menopause.

[103]  J. Lavoie,et al.  The effect of the menopausal transition on body composition and cardiometabolic risk factors: a Montreal-Ottawa New Emerging Team group study , 2012, Menopause.

[104]  T. D. de Villiers,et al.  The WHI: the effect of hormone replacement therapy on fracture prevention , 2012, Climacteric : the journal of the International Menopause Society.

[105]  P. Sluss,et al.  Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging , 2012, Menopause.

[106]  P. Sluss,et al.  Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. , 2012, The Journal of clinical endocrinology and metabolism.

[107]  P. Sluss,et al.  Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging , 2012, Climacteric : the journal of the International Menopause Society.

[108]  E. Grunfeld,et al.  Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial , 2012, The Lancet. Oncology.

[109]  M. V. van Aalst,et al.  The impact of menopausal symptoms on work ability , 2012, Menopause.

[110]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[111]  H. Thacker.  Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women. , 2011, Journal of women's health.

[112]  C. Klipping,et al.  Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive , 2011, Drugs in R&D.

[113]  B. Littenberg,et al.  Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. , 2011, The oncologist.

[114]  C. Labrie,et al.  Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia , 2011, Climacteric : the journal of the International Menopause Society.

[115]  O. Ylikorkala,et al.  [Hormone therapy and risk for breast cancer in Finnish postmenopausal women]. , 2011, Duodecim; laaketieteellinen aikakauskirja.

[116]  N. Panay,et al.  Recommendations for the management of postmenopausal vaginal atrophy , 2010, Climacteric : the journal of the International Menopause Society.

[117]  J. Ockene,et al.  Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial , 2010, Menopause.

[118]  S. Suissa,et al.  Hormone replacement therapy and the risk of venous thromboembolism: a population‐based study , 2010, Journal of thrombosis and haemostasis : JTH.

[119]  B. Nan,et al.  Amount of bone loss in relation to time around the final menstrual period and follicle-stimulating hormone staging of the transmenopause. , 2010, The Journal of clinical endocrinology and metabolism.

[120]  S. Ho,et al.  Menopausal transition and changes of body composition: a prospective study in Chinese perimenopausal women , 2010, International Journal of Obesity.

[121]  P. Dubey,et al.  A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. , 2010, The journal of sexual medicine.

[122]  C. Loprinzi,et al.  Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  W. Rocca,et al.  Premature menopause or early menopause: long-term health consequences. , 2010, Maturitas.

[124]  Yang Xue-zhi.  Influence of different routes of administration of Mongolian medicine Naru-3 on rabbit plasma concentration , 2010 .

[125]  F. Greenway,et al.  An Endocrine Society Clinical Practice Guideline Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: , 2010 .

[126]  I. Lambrinoudaki,et al.  Additive effect of depressed mood and vasomotor symptoms on postmenopausal insomnia , 2009, Menopause.

[127]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[128]  P. Novotny,et al.  Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  Nananda F Col,et al.  Menopause , 2009, Annals of Internal Medicine.

[130]  N. Rance,et al.  Changes in Prodynorphin Gene Expression and Neuronal Morphology in the Hypothalamus of Postmenopausal Women , 2008, Journal of neuroendocrinology.

[131]  V. Henderson.  Cognitive changes after menopause: influence of estrogen. , 2008, Clinical obstetrics and gynecology.

[132]  S. Cummings,et al.  The effects of tibolone in older postmenopausal women. , 2008, The New England journal of medicine.

[133]  E. Diczfalusy,et al.  Estetrol: A unique steroid in human pregnancy , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[134]  F. Clavel-Chapelon,et al.  Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  R. Norman,et al.  Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. , 2008, The journal of sexual medicine.

[136]  G. Hammond,et al.  Estetrol does not bind sex hormone binding globulin or increase its production by human HepG2 cells , 2008, Climacteric : the journal of the International Menopause Society.

[137]  J. Foidart,et al.  In vitro effects of estetrol on receptor binding, drug targets and human liver cell metabolism , 2008, Climacteric : the journal of the International Menopause Society.

[138]  Lin Shou-qin,et al.  The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women:2007 position statement of The North American Menopause Society , 2008 .

[139]  P. Delmas,et al.  Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women , 2008, Osteoporosis International.

[140]  B. Johansson,et al.  Pelvic floor sex steroid hormone receptors, distribution and expression in pre‐ and postmenopausal stress urinary incontinent women , 2007, Acta obstetricia et gynecologica Scandinavica.

[141]  L. Melton,et al.  Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause , 2007, Neurology.

[142]  P. Chambon,et al.  Estrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in Osteoclasts , 2007, Cell.

[143]  A. Coomarasamy,et al.  Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review , 2007, Archives of Gynecology and Obstetrics.

[144]  M. Lock,et al.  Oxybutynin for refractory hot flashes in cancer patients , 2007, Menopause.

[145]  B. L. Riggs,et al.  Effect of Blockade of TNF‐α and Interleukin‐1 Action on Bone Resorption in Early Postmenopausal Women , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[146]  T. Clarkson.  Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression , 2007, Menopause.

[147]  G. Bachmann,et al.  The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society , 2007, Menopause.

[148]  A. Ferenczy,et al.  Endometrial effects of tibolone. , 2007, The Journal of clinical endocrinology and metabolism.

[149]  M. Yosef,et al.  Changes in body composition in women over six years at midlife: ovarian and chronological aging. , 2007, The Journal of clinical endocrinology and metabolism.

[150]  E. Salpeter,et al.  Meta‐analysis: effect of hormone‐replacement therapy on components of the metabolic syndrome in postmenopausal women , 2006, Diabetes, obesity & metabolism.

[151]  A. LaCroix,et al.  Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. , 2005, Archives of internal medicine.

[152]  N. Page.  New challenges in the study of the mammalian tachykinins , 2005, Peptides.

[153]  H Kuhl,et al.  Pharmacology of estrogens and progestogens: influence of different routes of administration , 2005, Climacteric : the journal of the International Menopause Society.

[154]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[155]  Hui Lin,et al.  The role of anxiety and hormonal changes in menopausal hot flashes , 2005, Menopause.

[156]  B. Hulka,et al.  Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. , 2004, Maturitas.

[157]  K. Matthews,et al.  Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of Women's Health Across the Nation. , 2004, American journal of epidemiology.

[158]  B. Howard,et al.  Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial , 2004, Diabetologia.

[159]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[160]  R Don Gambrell,et al.  Women's Health Initiative , 2001 .

[161]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[162]  B. Ansell.  The metabolic syndrome in postmenopausal women , 2003 .

[163]  G. Chaudhuri,et al.  Correlation of androgen receptors, aromatase, and 5-alpha reductase in the human vagina with menopausal status. , 2003, Fertility and sterility.

[164]  Leslie Carol Botha.  Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women , 2003 .

[165]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[166]  R. Marcus,et al.  The role of calcium in peri- and postmenopausal women: 2006 position statement of The North American Menopause Society , 2006, Menopause.

[167]  S. Davis,et al.  Minireview: Aromatase and the Regulation of Estrogen Biosynthesis-Some New Perspectives. , 2001, Endocrinology.

[168]  J. Elmore,et al.  Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. , 2001, Journal of the National Cancer Institute.

[169]  W. Mack,et al.  Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women , 2001, Menopause.

[170]  H. Kloosterboer.  Tibolone: a steroid with a tissue-specific mode of action , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[171]  K. Schmidt-Gollwitzer.  Estrogen/hormone replacement therapy present and past , 2001 .

[172]  P. Cardon,et al.  A qualitative study. , 2001 .

[173]  D. Reboussin,et al.  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000, The New England journal of medicine.

[174]  G. Bachmann,et al.  Diagnosis and treatment of atrophic vaginitis. , 2000, American family physician.

[175]  J. Kelsey,et al.  Menopause : biology and pathobiology , 2000 .

[176]  F. Grodstein,et al.  Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. , 1999, The American journal of medicine.

[177]  V. Hasselblad,et al.  Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis , 1998, Obstetrics and gynecology.

[178]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[179]  N. Hébert-croteau.  A meta-analysis of hormone replacement therapy and colon cancer in women. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[180]  K. Yaffe,et al.  Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. , 1998, JAMA.

[181]  N. Wintfeld,et al.  Postmenopausal hormone therapy and mortality. , 1997, The New England journal of medicine.

[182]  S. Davis,et al.  Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. , 1997, The New England journal of medicine.

[183]  Elaine C. Stephens,et al.  Urogenital ageing and its effect on sexual health in older British women , 1997, British journal of obstetrics and gynaecology.

[184]  Susan R. Johnson,et al.  Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. , 1996, JAMA.

[185]  C. Egarter,et al.  Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. , 1996, Maturitas.

[186]  D. Herrington,et al.  Regression of atherosclerosis in female monkeys. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[187]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[188]  P. Ganz,et al.  Estrogen Improves Endothelium-Dependent, Flow-Mediated Vasodilation in Postmenopausal Women , 1994, Annals of Internal Medicine.

[189]  W. Stamm,et al.  A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. , 1993, The New England journal of medicine.

[190]  V. Medvei.  The History of Clinical Endocrinology: A Comprehensive Account of Endocrinology from Earliest Times to the Present Day , 1993 .

[191]  Karl Tombre,et al.  Summary and Recommendations , 1992, Diabetes Care.

[192]  E. Gurpide,et al.  In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium. , 1990, Journal of steroid biochemistry.

[193]  T. D. Whittet.  Drug Discovery: the Evolution of Modern Medicines. , 1987 .

[194]  R. Lobo.  Absorption and metabolic effects of different types of estrogens and progestogens. , 1987, Obstetrics and gynecology clinics of North America.

[195]  O. B. Schaffalitzky de Muckadell,et al.  Flushing and plasma substance P concentration during infusion of synthetic substance P in normal man. , 1986, Scandinavian journal of gastroenterology.

[196]  J. Gielen,et al.  15- and 16-hydroxylations of androgens and estrogens in the human fetal liver: a critical step in estetrol biosynthesis. , 1985, Journal of steroid biochemistry.

[197]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[198]  M. Whitehead,et al.  Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. , 1981, The New England journal of medicine.

[199]  M. Pike,et al.  Estrogens and endometrial cancer in a retirement community. , 1976, The New England journal of medicine.

[200]  D. Thompson,et al.  Association of exogenous estrogen and endometrial carcinoma. , 1975, The New England journal of medicine.

[201]  H. Ziel,et al.  Increased risk of endometrial carcinoma among users of conjugated estrogens. , 1975, The New England journal of medicine.

[202]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.

[203]  K. Slotta,et al.  Reindarstellung der Hormone aus dem Corpus luteum (II. Mitteil.) , 1934 .

[204]  W. M. Allen,et al.  CRYSTALLINE PROGESTIN. , 1934, Science.

[205]  A. Butenandt,et al.  Zur Isolierung und Charakterisierung des Corpus‐luteum‐Hormons , 1934 .

[206]  K. Slotta,et al.  Reindarstellung der Hormone aus dem Corpus luteum. (Vorläuf. Mitteil.) , 1934 .

[207]  A. Wettstein,et al.  Ein krystallisiertes Hormon aus Corpus luteum. (Vorläufige Mitteilung) , 1934 .

[208]  E. A. Doisy,et al.  THE PREPARATION OF THE CRYSTALLINE OVARIAN HORMONE FROM THE URINE OF PREGNANT WOMEN , 1930 .

[209]  G. Fraedrich,et al.  Juvenile recurrent respiratory papillomatosis: Still a mystery disease with difficult management , 2007, Head & neck.